Verona Pharma Granted Key EU Patent for Late-stage COPD Clinical Candidate Ensifentrine

Verona Pharma (NASDAQ:VRNA, AIM:VRP) has announced that the European Patent Office granted another key patent regarding its lead development candidate,...

Verona Pharma Announces Publication of Key Paper on RPL554 in COPD in the European Respiratory Journal

Verona Pharma (AIM:VRP) (Nasdaq:VRNA) a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today announced...